INS and type 1 diabetes mellitus: Considering that body mass index (BMI), body composition and diet of Iranian populations are different from those in other populations,23,24 the present clinical trial was conducted to evaluate the beneficial effects of empagliflozin on HbA1c levels, as a primary outcome, and fasting blood sugar (FBS), blood sugar 2-hour post prandial (BS 2hpp), insulin doses, and anthropometric indices (BMI, waist/hip ratio [WHR], waist/height ratio [WHtR]), as secondary outcomes, in Iranian patients with T1D.